InvestmentApr 15, 2026, 12:42 AM
Revolution Medicines Prices $2B Concurrent Offerings
AI Summary
Revolution Medicines announced the pricing of concurrent public offerings, raising approximately $1.5 billion from common stock and $500 million from 0.50% convertible senior notes due 2033. Both offering sizes were increased from previously announced amounts, indicating strong investor interest. The common stock was priced at $142.00 per share, and the notes have an initial conversion price of approximately $198.80 per share, representing a 40.0% premium. The company estimates net proceeds from the common stock offering to be about $1.435 billion, which will support its late-stage clinical oncology programs.
Key Highlights
- Priced $1.5 billion common stock offering at $142.00 per share.
- Priced $500 million 0.50% convertible senior notes due 2033.
- Initial conversion price for notes is $198.80 per share, a 40.0% premium.
- Common stock offering size increased from $750M; note offering from $250M.
- Net proceeds from common stock offering estimated at $1.435 billion.